Central nervous system involvement in patients with diffuse large B cell lymphoma: analysis of the risk factors and prognostic from a single-center retrospective cohort study

Jingjing Ma
Huashan Hospital North, Fudan University

Qing Li
Huashan Hospital North, Fudan University

Jie Shao
Huashan Hospital North, Fudan University

Yan Ma
Huashan Hospital North, Fudan University

Zhiguang Lin
Huashan Hospital Fudan University

Hui Kang
Huashan Hospital North, Fudan University

Bobin Chen (✉ bbchen@fudan.edu.cn)
https://orcid.org/0000-0002-1826-4974

Research article

Keywords: Diffuse large B-cell lymphoma; Central nervous system involvement; Risk factors; Prognostic

Posted Date: October 14th, 2019

DOI: https://doi.org/10.21203/rs.2.13767/v2

License: ☎️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Cancer Management and Research on December 1st, 2019. See the published version at https://doi.org/10.2147/CMAR.S225372.
Abstract

Purpose The aim of this study was to identify the risk factors for central nervous system (CNS) involvement in systemic diffuse large B-cell lymphoma (DLBCL) patients and to explore prognostic for DLBCL patients with CNS involvement (relapse or progression). Method This was a retrospective cohort study in our hospital. Data were collected from all DLBCL patients diagnosed in our institutes from January, 2013 to June, 2018. Clinical information was collected from medical records. Result The participants included 138 patients with DLBCL. Among them, 38 patients were diagnosed as CNS lymphoma, including 15 patients exhibited CNS involvement while DLBCL were pathologically confirmed, and 23 patients developed CNS lymphoma during or after initial chemotherapy. The median disease-free interval to CNS involvement was 13 months. Multivariate analysis identified elevated serum lactate dehydrogenase (LDH) level [hazard ratio (HR) = 4.035; 95% confidence interval (95%CI): 1.147~14.195] was independent predictor of CNS involvement. The median progression-free survival (PFS) and overall survival (OS) time of DLBCL patients with CNS involved were 12.5 months and 22 months, respectively. Multivariate prognostic analysis showed that eastern cooperative oncology group (ECOG) score > 2 (P=0.018; HR=7.333; 95%CI: 1.424~42.002), elevated serum LDH level (P=0.046; HR=6.510; 95%CI: 1.035~40.949), deep lesion (P=0.005; HR=10.957; 95%CI: 2.050~58.569), and CNS with systemic involvement (P=0.023; HR=2.730; 95%CI: 1.151~6.479) were independent poor prognostic factors for the patients. The cases with lymphocyte absolute count > 0.75×10⁹/L (HR=0.047; 95%CI: 0.003~0.732) had better prognosis. The OS of DLBCL patients with secondary CNS lymphoma was inferior to DLBCL patients without CNS involvement. There was no significant difference between the patients with CNS and extra-CNS involvement. There was no significant difference between the patients with CNS involvement and stage III-IV DLBCL cases without CNS lymphoma. Conclusion In conclusion, elevated serum LDH was independent high-risk factor for secondary CNS lymphoma. For patients DLBCL with CNS involvement, ECOG score > 2, elevated serum LDH level, deep lesion, lymphocyte absolute count ≤0.75×10⁹/L and CNS with systemic involvement retained a significant association with outcome.

Background

Diffuse large B-cell lymphoma (DLBCL) is the most common pathological type of non-Hodgkin lymphoma [1]. Although monoclonal anti-CD20 antibody rituximab (R) combined with chemotherapy improves the remission rate and prolongs overall survival (OS), secondary central nervous system (SCNS) involvement in DLBCL (including relapse or progression) seriously affects the efficacy of treatments for DLBCL [2-3]. In the past literature, the incidence of CNS involvement is about 5-20% [3-4]. Age>60 years, Elevated serum LDH, high international prognostic index (IPI), Ann Arbor stage III-IV, extranodal sites involvement, and involvement of specifically extranodal sites which contains kidney, breast or testes are the most frequently reported high risk factors of CNS involvement [3,5,6-10]. Whether rituximab (R) combined with chemotherapy and prophylactic intrathecal therapy can reduce the risk of CNS involvement remains controversial [3,4,7,9]. Early identification and screening for CNS involvement risk
factors with close follow-up or early prevention are expected to improve both the efficacy of treatments for and the prognosis of this disease\textsuperscript{[11-13]}. Due to rapid tumor growth and lack of effective treatment strategies, the prognosis of DLBCL patients with CNS involvement is very poor, and the median survival time is approximately 2 to 6 months \textsuperscript{[5]}. Long time survivors are rarely observed. Therefore, the treatment for DLBCL with CNS involvement is in urgent need of improvement. However, there were few studies reported the prognostic factors for DLBCL patients with CNS involvement. There is no effective prognostic model for the disease.

The aim of this study was to reveal the risk factors associated with CNS involvement in patients with DLBCL and to explore prognostic for DLBCL patients with CNS involvement. 38 DLBCL patients with CNS involvement were admitted to our hospital, and their clinical characteristics, risk factors and prognosis were analyzed.

**Methods**

2.1 Patients and clinical data

A total of 138 DLBCL patients were recruited at our center from January 1, 2013 to June 31, 2018. All patients were followed up until 31 December 2018. In total 138 patients, there were 38 patients had CNS involvement. Among these 38 patients, 15 patients exhibited CNS involvement while DLBCL were pathologically confirmed 15 patients exhibited CNS involvement at initial diagnosis of DLBCL, and 23 patients developed CNS involvement during or after initial chemotherapy. When we analyzed the risk factors of CNS involvement in DLBCL patients, 15 patients with CNS involvement at the time of diagnosis were excluded. All cases initial diagnosis of DLBCL were based on the pathological diagnosis of lymph node or organ biopsy.

2.2 Diagnosis of CNS involvement

CNS involvement was determined according to the findings of magnetic resonance imaging (MRI) or cerebrospinal fluid tests together with symptoms of CNS. For patients with suspected CNS lymphoma, biopsy or surgical resection should be performed for pathological confirmation, if possible. CNS involvement was limited to the eyes, leptomeningeal, spinal cord and brain parenchyma. Epidural involvement was excluded from the CNS manifestation.

2.3 Treatment of newly diagnosed DLBCL

All patients newly diagnosed with DLBCL who accepted the CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or R-CHOP standard chemotherapy regimens were treated according to the patient's wishes.

2.4 Statistical analysis
We used descriptive statistics to summary patient’s clinical characteristics. Qualitative data were compared by chi-square test, and the strength of risk factors was calculated as the odds ratio (OR) and corresponding 95%CI. Univariate survival analysis was performed with the log-rank test. A Cox regression model was used for multivariate analysis of prognosis. A Kaplan-Meier curve was used to calculate the progression-free survival and overall survival durations. P-values less than 0.05 were considered statistically significant. All data were analyzed using the Stata 12.0 software package.

Results

3.1 Baseline characteristics of 123 newly diagnosed DLBCL patients.

None of the 123 newly diagnosed DLBCL patients presented CNS involvement. The clinical characteristics of 123 DLBCL patients, including 65 males and 58 females, were examined. The median age of initial DLBCL onset was 54 (41-85) years. The ECOG score was 0-2 in 96 cases (78%) and 3-4 in 27 cases (22%). Seventeen patients (13.8%) were diagnosed with DLBCL as a bulky disease. Thirty-three patients (26.8%) suffered from extranodal site involvement (excluding the CNS) at the time of onset. At onset, 57 patients (46.3%) were stage III-IV, and 66 patients (53.7%) were stage I-II. The IPI was >2 in 53 patients (43.1%) and ≤2 in the remaining 70 (56.9%) patients at onset. The LDH level was higher than normal in 42 patients (34.1%). Thirty-five patients (43%) had germinal center B-cell-like (GCB) disease, fifty-two patients (30%) had non-GCB disease, and the pathological type in the remaining 36 patients was unclassified. Bone marrow involvement occurred in 17 patients (13.8%). A total of 100 patients (81.3%) were treated with rituximab and 42 patients (34.1%) were treated with dorubicin liposome.

3.2 Univariate and multivariate analysis of CNS involvement risk factors.

Of the one hundred and twenty-three cases with DLBCL, 23 patients developed CNS involvement, some due to disease progression and some due to relapse. The incidence of CNS involvement was 18.7%. All patients were analyzed as shown in the following table (Table1). Several factors were analyzed, including age, gender, ECOG score, bulky disease, extranodal site involvement, Ann Arbor stage, IPI, serum LDH, GCB or Non-GCB pathological type, bone marrow involvement, prophylactic intrathecal injection therapy, whether use rituximab and dorubicin liposome, etc. Univariate analysis showed that ECOG score (P=0.006; OR=3.756), IPI (P=0.005; OR=3.892), Ann Arbor stage III-IV (P=0.003; OR=4.25), Elevated serum LDH level (P=0.012; OR=3.183) were high-risk factors for DLBCL patients developing CNS involvement. Use dorubicin liposome (P=0.018; OR=0.235) was protective factor for DLBCL patients developing CNS involvement. The other factors, including age, gender, bulky disease, extranodal sites involvement, bone marrow involvement, GCB or Non-GCB pathological type and rituximab use before CNS involvement were not predictive of CNS involvement by univariate analysis. Multivariate analysis identified LDH (P=0.030; HR=4.035; 95%CI: 1.147~14.195) was as independent predictor of CNS involvement (Table 2).

3.3. Baseline characteristics, treatment, and outcome of 38 DLBCL patients with CNS involvement.
Table 3 showed that the baseline characteristics of 38 DLBCL patients with CNS involvement. From the total of 38 patients of DLBCL with CNS involvement, 15 patients had CNS involvement at initial diagnosis of DLBCL, and 23 patients were diagnosed with CNS involvement during or after first-line chemotherapy. Isolated CNS involvement occurred in 11 patients, while CNS involvement plus systemic disease occurred in 27 patients. First-line treatment for DLBCL patients with CNS involvement were different, which included high-dose methotrexate (HD-MTX) only (n=3), MTX combined CHOP (n=11), MTX combined R-CHOP (n=13), CHOP (n=4), DHAP (Dexamethasone, Cisplatin, Cytarabine) (n=2), MTX combined Idarubicin (IDA) (n=2), whole-brain radiotherapy (WBRT) (n=2), no treatment (n=1). For patients with leptomeningeal abnormal, lumbar puncture and intrathecal injection chemotherapy were given as routine treatment. In our center, we often intrathecal injection MTX–cytarabine (Ara-C) and dexamethasone (n=17). In the patients treated with HD-MTX, we used the MTX dose was 3.5-8g/m². After 2-4 cycles of chemotherapy or one cycle of radiotherapy, 23 patients showed rapid progression. We administered second-line treatment i.e., DHAP, ICE (Ifosfamide, Carboplatin, Etoposide), Ara-C combined with temozolomide (TMZ), and WBRT. In addition, there were four patients treated with autologous hematopoietic stem cell transplantation (ASCT).

In total, the median follow-up time was 2 years (range from 0.5 to 5.5 years). There were 15 patients (39.5%) died, 13 patients (34.2%) were in complete remission (CR), 3 patients (7.9%) were in progression disease (PD), 5 patients (13.2%) were in partial remission (PR), and 2 patients (5.2%) were in stable disease (SD). The median PFS time after CNS involvement was 12.5 months. The median OS time after CNS involvement was 22 months.

3.4 Analysis of prognostic factors at the time of CNS involvement.

Univariate analysis by log-rank test and multivariate analysis by cox multiple regression were performed to analyze prognostic factors among 38 patients of DLBCL with CNS involvement. Univariate prognostic analysis showed that ECOG score>2 (P=0.002; HR=5.215; 95%CI:1.842~14.76), cerebrospinal fluid (CSF) protein>1.0g/L (P=0.004; HR=10.84; 95%CI:2.165~54.32), lymphocyte absolute count ≤0.75*10⁹/L (P=0.023; HR=8.857; 95%CI:1.999~39.25) and elevated LDH level (P=0.005; HR=5.355; 95%CI:1.648~17.4) were poor prognostic factors (Table 4). Multivariate prognostic analysis identified ECOG score>2 (P=0.018; HR=7.333; 95%CI:1.424~42.002), elevated LDH level (P=0.046; HR=6.510; 95%CI:1.035~40.949), deep lesion (defined as lesions located more than 3 centimeters from the brain surface) (P=0.005; HR=10.957; 95%CI:2.050~58.569), and CNS with systemic involvement (P=0.023; HR=2.730; 95%CI:1.151~6.479) were independent poor prognostic factors. Lymphocyte absolute count ≤0.75*10⁹/L (P=0.029; HR=0.047; 95%CI:0.003~0.732) was protective prognostic factor (Table 5). Other factors, such as gender, age≥60 years, bulky disease, CSF nuclear cells, neutrophil absolute count ≥6.3*10⁹/L, peripheral blood white blood cell (WBC) and site of CNS involvement had no impact on prognosis (P>0.05). We use these five factors (ECOG>2, elevated LDH level, deep lesion, CNS with systemic involvement, Lymphocyte absolute count ≤0.75*10⁹/L) established a simple prognostic score system,
with one point with each term, and divided into three groups of low (0-1 point), medium (2-3 point) and high risk (4-5 point), with one year survival rate of 90.9%, 40% and 14.3% respectively.

**3.5 Kaplan-Meier curve estimation of PFS and OS of DLBCL patients with and without CNS involvement.**

The result revealed that the median PFS and OS durations of DLBCL patients after CNS involvement were 12.5 months and 22 months, respectively (Fig 1-2). As shown in our research, the overall survival of DLBCL patients with CNS involvement (SCNSL) was poorer than DLBCL patients without CNS involvement (P=0.032; HR=2.282; 95%CI: 1.075~4.842) (Fig 3). It is notable that there was no difference observed between the cases with CNS and extra-CNS involvement (P=0.181; HR=0.482; 95%CI: 0.165~1.405). There was no difference observed between the patients with CNS involvement at the time of DLBCL diagnosed and during or after first-line therapy (P=0.973; HR=1.182; 95%CI: 0.429~3.259). There was no significant difference between the patients with CNS involvement and stage III-IV DLBCL cases without CNS involvement (P=0.238; HR=1.555; 95%CI: 0.747~3.238) (Fig 4-6)

**Discussion**

The incidence of CNS involvement in DLBCL ranges from 5% to 20% [3-4], at 10% in Asian countries and 5% in European countries. CNS involvement in DLBCL mainly occurs within less than one year after diagnosis, after a median of 6 months [9,14-15]. CNS involvement in DLBCL is divided into the following three scenarios: (1) patients with systemic remission, simple recurrence of CNS involvement; (2) patients achieve remission after treatment, but systemic recurrence with CNS involvement occur at the same time; and (3) patients develop CNS involvement early in the treatment period (within 6 months). The CNS involvement can manifest in the brain parenchyma, leptomeningeal, spinal cord and eyes. Therefore, DLBCL patients with suspected CNS involvement should be examined by cerebrospinal fluid cytology, contrast-enhanced head and spinal cord MRI and eye Doppler ultrasound. If necessary and possible, diagnostic vitrectomy and brain biopsy should be performed to confirm the diagnosis. The incidence of CNS involvement in this study was higher than that previously reported in European and American countries. This discrepancy may be related to race, the higher proportion of selected patients in the high-risk group and the longer follow-up period of our study. Previous studies have reported that age>60 years, high LDH, ECOG score>2, IPI>2, multiple extranodal site involvement, bone marrow involvement, and Ann Arbor stage III-IV are risk factors of CNS involvement [5,6-10]. Other studies have shown that the involvement of special anatomical sites, such as the breasts, testes, nasopharynx, adrenal glands, or bone marrow, are risk factors of CNS involvement [9-10]. Whether rituximab combined with chemotherapy and prophylactic intrathecal therapy can reduce the risk of CNS involvement remains controversial [3,4,7,9]. In our study, univariate analysis showed that ECOG score≥2, IPI≥2, Ann Arbor stage III-IV, Elevated serum LDH level were high-risk factors for DLBCL patients developing CNS involvement and use of doxorubicin liposome was protective factors for DLBCL patients developing CNS involvement. Compared with previous related studies, our study identified that elevated serum LDH was the independent high-risk factor of CNS involvement from multivariate analysis. A few studies have shown that the use of...
rituximab can reduce the incidence of CNS \cite{3}. This conclusion is currently controversial \cite{4,9}. We found that the use of rituximab did not prevent CNS involvement. This conclusion may be related to the limitations of selection bias in retrospective studies. Since our patients did not routinely receive prophylactic intrathecal injection, we did not analyze the effect of prophylactic intrathecal injection on CNS involvement. In conclusion, close attention should be paid to DLBCL patients with high-risk factors, who may require early preventive treatment.

Previous studies have shown that DLBCL patients with CNS involvement have a poor prognosis, with a median OS duration of 2-6 months \cite{5}. We found that the median PFS and OS durations of DLBCL patients after CNS involvement were 12.5 months and 22 months, respectively (Fig 1-2). Univariate analysis and multivariate analysis were performed to analyze prognostic factors among 38 patients of DLBCL with CNS involvement. Univariate prognostic analysis showed that ECOG score>2, CSF protein>1.0g/L, lymphocyte absolute count ≤0.75´10^9/L and elevated LDH level were poor prognostic factors (Table 4). Multivariate prognostic analysis identified ECOG score>2, elevated LDH level, deep lesion, and CNS with systemic involvement were independent poor prognostic factors. Lymphocyte absolute count ≥0.75´10^9/L was protective prognostic factor (Table 5). We use these five factors (ECOG ≥2, elevated LDH level, deep lesion, CNS with systemic involvement, Lymphocyte absolute count ≤0.75´10^9/L) established a simple prognostic score system, with one point with each term, and divided into three groups of low (0-1 point), medium (2-3 point) and high risk (4-5 point), with one year survival rate of 90.9%, 40% and 14.3% respectively. However, due to the lack of sufficient sample, it is impossible to establish a reliable prognostic model. In future, we plan to collect more cases and make more reliable prognostic model for the disease.

As shown in our research, the prognosis of DLBCL patients with CNS involvement was poorer than DLBCL patients without CNS involvement (Fig 3). Unlike previous study, our research found that there was no difference in overall survival between the cases with CNS and extra-CNS involvement. There was no difference observed between the patients with CNS involvement at the time of DLBCL diagnosed and during or after initial therapy. Meanwhile it is notable that there was no significant difference in overall survival between the patients with CNS involvement and stage III-IV DLBCL cases without CNS involvement (Fig 4-6).

DLBCL patients with CNS involvement can be treated with WBRT, HD-MTX, polychemotherapy and autologous HSCT. The usefulness of WBRT is limited by its toxicity, especially in older patients; its true impact on outcome remains controversial \cite{16}. HD-MTX is often effective in cases of primary and secondary CNS lymphoma; however, it is very important to determine whether the CNS involvement is sensitive to MTX. In MTX-sensitive patients, HD-MTX administration is advisable, followed by thiotepa or carmustine-based conditioning regimens and autologous HSCT \cite{17}. Other agents that cross the blood-brain barrier, such as HD-cytarabine or ifosfamide, have been used in combination with HD-MTX and have shown encouraging efficacy \cite{17-20}. Other regimens, such as HD-MTX combined with IV rituximab or IV HD-cytarabine combined with oral temozolomide, may be feasible options \cite{21}. Patients with resistant
lymphoma should be candidates for clinical trials or other palliative treatment\cite{17,22}. In our center, we tried to take effective measures to prolong the patients’ survival time. For most part of patients with CNS involvement, we considered both CNS and systemic regimens, and selected HD-MTX (3.5-8g/m$^2$) combined CHOP or R-CHOP as the first-line treatment regimen. Meanwhile for patients with leptomeningeal abnormal, lumbar puncture and intrathecal injection chemotherapy were given as routine treatment. After 2-4 cycles of chemotherapy or one cycle of radiotherapy, 23 patients showed rapid progression. We administered second-line treatment i.e., DHAP, ICE, Ara-C combined with TMZ, and WBRT. In addition, there were four patients treated with ASCT. In total, the median follow-up time was 2 years (0.5-5.5 years). There were 15 patients (39.5%) died, 13 patients (34.2%) were in complete remission (CR), 3 patients (7.9%) were in progression disease (PD), 5 patients (13.2%) were in partial remission (PR), and 2 patients (5.2%) were in stable disease (SD). The overall response rate was 47.4%.

**Conclusions**

Among DLBCL patients, elevated serum LDH was independent high-risk factor for CNS involvement. Close attention should be paid to DLBCL patients with high-risk factors, who may require early preventive treatment. For patients with CNS involvement, ECOG score >2, deep lesion and CNS with systemic involvement were independent poor prognostic factors for the patients. The cases with lymphocyte absolute count >0.75$\times$10$^9$/L had better prognosis. The prognosis of DLBCL patients with CNS involvement was inferior. The median PFS time after-CNS involvement was 12.5 months. The median OS time after-CNS involvement was 22 months. Unlike previous study, our research found that there was no difference in overall survival between the cases with CNS and extra-CNS involvement. There was no difference observed between the patients with CNS involvement at the time of DLBCL diagnosed and during or after first-line therapy. Meanwhile it is notable that there was no significant difference in overall survival between the patients with CNS involvement and the patients of DLBCL stage III-IV without CNS involvement.

**Declarations**

**Ethics approval and consent to participate:** This research was approved by Ethics Committee of Huashan Hospital North, Fudan University. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Consent to participate is not applicable.

**Consent for publication:**

Not applicable.

**Availability of data and material:**

Not applicable.
**Competing interests**

The authors declare that they have no competing interests.

**Funding:**

This retrospective study is a part of research (No.16CR2043B) which funded by the Shanghai Shenkang Hospital Development Center: Three-year Plan for Promoting Clinical Skills and Innovations in Municipal Hospitals

**Authors' contributions:**

JJM, QL and BBC conceived and designed the study. JJM and QL performed all the data collected and analysis. JJM wrote the paper. JS, YM, HK, ZGL and BBC reviewed and edited the manuscript. All authors read and approved the manuscript.

**Acknowledgements:**

Thanks a lot for the contributions both of the researchers and the study participants.

**References**

1. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015; 90:790-795. DOI: 10.1002/ajh.24086.

2. Abramson, J. S. High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen. Haematologica. 98,662–664 (2013). DOI:10.3324/haematol.2013.084285

3. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(3):509–514. DOI:10.3109/10428194.2013.811239

4. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol, 2011,90:809-818. DOI:1007/s00277-010-1150-7

5. Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014;55(10):2228–2240. DOI:10.3109/10428194.2013.869326

6. Van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178–1184. DOI:1006/bcmd.1998.0171
7. Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. 2012; 118(11):2944–2951. DOI 10.1002/cncr.26588

8. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5): 1267–1273. DOI 1093/annonc/mdr440

9. Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2):245–251. DOI 1111/j.1349-7006. 2011. 02139.x

10. Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3):358–363. DOI 1111/bjh.12753

11. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence or rituximab. Ann Oncol. 2004;15(1):129–133. DOI 1093/annonc/mdh013

12. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–3902. DOI 1182/blood-2008-10-182253

13. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2009;21(5):1046–1052. DOI 1093/annonc/mdp432

14. Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12):2270–2275. DOI 10428194.2011.596966

15. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Rev. 2012;26(3):97–106. DOI 1016/j.blre.2011.12.001

16. Graber JJ, Omuro A. Primary central nervous system lymphoma: is there still a role for radiotherapy? Curr Opin Neurol. 2011;24(6):633–640. DOI 1097/WCO.0b013e32834cbdef

17. Rubenstein JL, Gupta NK, Mannis GN, LaMarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14):2318–2330. DOI 11182/blood-2013-06-453084

18. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009;88(2):133–139. DOI 2214/AJR.07.3919

19. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Lancet. 2009;374(9700):1512–1520. DOI:1016/S0140-6736(09)61416-1

20. Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43(3):587–593. DOI:1080/10428190290012092

21. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101(1):139–145. DOI:1002/cncr.20339

22. Francisco-Javier Peñalver, Juan-Manuel Sancho, Adolfo de la Fuente, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica 2017;102(2):235-245. Doi:10.3324/haematol.2016.149120.

Tables

Table 1: Univariate analysis of risk factors for CNS involvement
Clinical features | CNS | Non-CNS | OR | 95%CI | \( \chi^2 \) | P value
--- | --- | --- | --- | --- | --- | ---
Gender | (n) | (n) | | | |
 Male | 15 | 50 | 1.875 | (0.701~4.773) | 1.738 | 0.187
 Female | 8 | 50 | | | |
Age(years) | | | | | |
 ≥60 | 11 | 47 | 1.034 | (0.419~2.480) | 0.005 | 0.943
 ≤60 | 12 | 53 | | | |
ECOG score | | | | | |
 ≥2 | 10 | 17 | 3.756 | (1.466~10.22) | 7.652 | 0.006
 ≤2 | 13 | 83 | | | |
Bulky disease | | | | | |
 Yes | 1 | 16 | 0.239 | (0.022~1.393) | 2.132 | 0.144
 No | 22 | 84 | | | |
Extranodal site involvement | | | | | |
 ≥2 | 8 | 25 | 1.6 | (0.599~4.054) | 0.912 | 0.340
 ≤2 | 15 | 75 | | | |
Stage | | | | | |
 III-IV | 17 | 40 | 4.25 | (1.614~11.56) | 8.649 | 0.003
 I-II | 6 | 60 | | | |
IPI | | | | | |
 ≥2 | 16 | 37 | 3.892 | (1.406~9.766) | 8.087 | 0.005
 ≤2 | 2 | 63 | | | |
LDH≥236 U/L | | | | | |
 Yes | 13 | 29 | 3.183 | (1.299~8.026) | 6.299 | 0.012
 No | 10 | 71 | | | |
GCB/Non-GCB | | | | | |
 GCB | 3 | 32 | 0.516 | (0.140~1.936) | 0.879 | 0.348
 Non-GCB | 8 | 44 | | | |
Bone marrow involvement | | | | | |
 Yes | 4 | 13 | 1.409 | (0.459~4.529) | 0.303 | 0.582
 No | 19 | 87 | | | |
Rituximab | | | | | |
 YES | 19 | 81 | 0.898 | (0.303~2.974) | 0.032 | 0.858
 No | 4 | 19 | | | |
Dorubicin liposome | | | | | |
 Yes | 3 | 39 | 0.235 | (0.070~0.806) | 5.603 | 0.018
 No | 20 | 61 | | | |

Table 2: Multivariate analysis of risk factors for CNS involvement

| Clinical factors | P value | Hazard ratio [95% Conf. Interval] |
|------------------|---------|---------------------------------|
| Gender(male/female) | 0.186 | 2.173(0.688~6.862) |
| Age≥60 years | 0.411 | 0.605(0.183~2.003) |
| ECOG≥2 | 0.111 | 3.166(0.767~13.057) |
| IPI≥2 | 0.084 | 4.564(0.815~25.547) |
| Elevated LDH | 0.030 | 4.035(1.147~14.195) |
| Stage I-II/III-IV | 0.859 | 0.861(0.164~4.522) |
| Extranodal involvement≥2 | 0.959 | 1.038(0.245~4.398) |
| Bulky disease | 0.059 | 0.113(0.012~1.088) |
| No use dorubicin liposome | 0.051 | 0.241(0.058~1.004) |
Table 3: Baseline characteristics of 38 DLBCL patients with CNS involvement

| Baseline characteristics | n  | %   |
|--------------------------|----|-----|
| Age (years)              |    | 59.84±8.711 |
| Gender                   |    |     |
| Male                     | 26 | 68.4% |
| Female                   | 12 | 21.6% |
| LDH                      |    |     |
| High (>236U/L)           | 15 | 42.9% |
| Normal (≤236U/L)         | 23 | 57.1% |
| Bulky Disease2           |    |     |
| Yes                      | 9  | 7.1%  |
| No                       | 29 | 92.9% |
| Sites                    |    |     |
| CNS only                 | 11 | 35.7% |
| CNS and systemic         | 27 | 64.3% |
| Deep lesion3             |    |     |
| Yes                      | 21 | 55.3% |
| No                       | 17 | 44.7% |
| CSF protein              |    |     |
| ≥1.0g/L                  | 13 | 43.3% |
| ≤1.0g/L                  | 17 | 66.7% |
| CSF nuclear cells        |    |     |
| ≥8*10⁶/L                 | 10 | 32.3% |
| ≤8*10⁶/L                 | 21 | 67.7% |
| CSF lymphoma cells       |    |     |
| Positive                 | 24 | 35.7% |
| Negative                 | 14 | 64.3% |
| Eyes involvement         |    |     |
| Yes                      | 7  | 7.1%  |
| No                       | 31 | 92.9% |

1 Mean±SD; 2 Bulky disease refers to the lesion diameter greater than 3cm; 3 deep lesions defined as lesions located more than 3cm from the brain surface.

Table 4: Univariate analysis of 38 DLBCL patients with CNS involvement.
| Ors | Median survival (Months) | Number (N) | Death (N) | HR 95%CI | $\chi^2$ | P value |
|-----|--------------------------|------------|-----------|----------|----------|----------|
|     |                          |            |           |          |          |          |
| 22  |                          | 26         | 11        | 1.063(0.332~3.399) | 0.011   | 0.918    |
| NR  |                          | 12         | 4         |          |          |          |
| 21  |                          | 21         | 11        | 2.683(0.940~7.663) | 3.399   | 0.065    |
| NR  |                          | 17         | 4         |          |          |          |
| 8   |                          | 19         | 13        | 5.215(1.842~14.76) | 9.678   | 0.002    |
| NR  |                          | 19         | 2         |          |          |          |
| L   |                          | 8          | 9         | 5.355(1.648~17.4) | 7.789   | 0.005    |
| NR  |                          | 23         | 6         |          |          |          |
| 8   |                          | 13         | 6         | 10.84(2.165~54.32) | 8.406  | 0.004    |
| NR  |                          | 17         | 7         |          |          |          |
| cell|                          | 21         | 11        | 2.254(0.782~6.495) | 2.265   | 0.132    |
| NR  |                          | 14         | 4         |          |          |          |
| count/L |                  | 3.5        | 2         | 8.857(1.999-39.25) | 5.025  | 0.023    |
| L   |                          | 31         | 13        |          |          |          |
| cell |                          | NR         | 21        | 1.586    |          | 0.452    |
| 9/L |                          | 21         | 7         |          |          |          |
|     |                          | 14         | 4         |          |          |          |
| count |                          | NR         | 24        | 3.202    |          | 0.074    |
| 9/L |                          | 21         | 12        |          |          |          |
|     |                          | 31         | 3         |          |          |          |
| (%) |                          | NR         | 16        | 1.269(0.424~3.793) | 0.182  | 0.670    |
|     |                          | 22         | 6         |          |          |          |
| (%) |                          | 14         | 21        | 2.483(0.862-7.153) | 2.837  | 0.092    |
|     |                          | NR         | 17        |          |          |          |
| ≥3cm|                          | 21         | 9         | 1.476(0.47~4.635) | 0.254  | 0.614    |
| 3cm |                          | 31         | 29        | 2.745(0.960~7.852) | 3.546  | 0.060    |
|     |                          | 21         | 12        |          |          |          |
|     |                          | NR         | 17        |          |          |          |
| involvement with |                  | 22         | 27        | 1.357(0.410~4.488) | 0.250  | 0.617    |
|     |                          | NR         | 11        |          |          |          |
| Involvement |                          | NR         | 21        | 4.931    |          | 0.085    |
| oral (incl. eye) |                  | 8          | 6         |          |          |          |
| retinal only     |                          | 8          | 2         |          |          |          |
| orbital only     |                          | 8          | 15        |          |          |          |
Table 5: Multivariate analysis of 38 DLBCL patients with CNS involvement.

| Multivariate Analysis: | Std. Err. | Z value | P value | HR      | 95% Conf. Interval |
|-----------------------|-----------|---------|---------|---------|--------------------|
| ≥60 years             | 0.861     | 0.053   | 0.951   | 1.054   | (0.195~5.694)      |
| G<2                  | 0.863     | 2.045   | 0.018   | 7.333   | (1.424~42.002)     |
| ≥236 U/L             | 0.938     | 1.873   | 0.046   | 6.510   | (1.035~40.949)     |
| protein≥1.0g/L       | 0.507     | 0.642   | 0.206   | 1.900   | (0.703~4.279)      |
| lymphocyte≥0.75*10^9/L | 1.406   | -3.067  | 0.029   | 0.047   | (0.003~0.732)      |
| lymphocyte (%)≥20%   | 0.899     | -0.308  | 0.732   | 0.735   | (0.126~4.279)      |
| lesion               | 0.855     | 2.395   | 0.055   | 10.957  | (2.050~58.569)     |
| neutrophil count≥6.3109/L | 1.025   | -1.078  | 0.293   | 0.340   | (0.046~2.538)      |
| Of Involvement (CNS + Systemic) | 0.441 | 1.004 | 0.023 | 2.730 | (1.151~6.479) |

Figures

![Figure 1](image.png)

**Figure 1**

Kaplan-Meier curve of the median OS durations of DLBCL patients after CNS involvement
Figure 2

Kaplan-Meier curve of the median PFS durations of DLBCL patients after CNS involvement
Figure 3

Kaplan-Meier curve of OS time between DLBCL patients with CNS involvement (SCNSL) and DLBCL patients without CNS involvement

Figure 4

Kaplan Meier curve of OS time between DLBCL patients with CNS and extra-CNS involvement
Figure 5

Kaplan Meier curve of OS time between the patients with CNS involvement at the time of DLBCL diagnosed and during or after first-line therapy.
Figure 6

Kaplan-Meier curve of OS time between the patients with CNS involvement and stage III-IV DLBCL cases without CNS involvement